+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019

  • ID: 4873222
  • Report
  • December 2019
  • Region: Global
  • 297 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • 3-D Matrix Ltd
  • Biom'Up SAS
  • CryoLife Inc
  • GATT Technologies BV
  • LifeBond Ltd
  • Sea Run Holdings Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019

Summary

The Medical Devices sector report, “Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019' provides an overview of Topical Absorbable Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Topical Absorbable Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Topical Absorbable Hemostats under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Topical Absorbable Hemostats and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Topical Absorbable Hemostats under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3-D Matrix Ltd
  • Biom'Up SAS
  • CryoLife Inc
  • GATT Technologies BV
  • LifeBond Ltd
  • Sea Run Holdings Inc

1 Introduction
1.1 Topical Absorbable Hemostats Overview
2 Products under Development
2.1 Topical Absorbable Hemostats - Pipeline Products by Stage of Development
2.2 Topical Absorbable Hemostats - Pipeline Products by Segment
2.3 Topical Absorbable Hemostats - Pipeline Products by Territory
2.4 Topical Absorbable Hemostats - Pipeline Products by Regulatory Path
2.5 Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date
2.6 Topical Absorbable Hemostats - Ongoing Clinical Trials
3 Topical Absorbable Hemostats - Pipeline Products under Development by Companies
3.1 Topical Absorbable Hemostats Companies - Pipeline Products by Stage of Development
3.2 Topical Absorbable Hemostats - Pipeline Products by Stage of Development
4 Topical Absorbable Hemostats Companies and Product Overview
4.1 3-D Matrix Ltd Company Overview
4.2 Angiotech Pharmaceuticals Inc Company Overview
4.3 Anika Therapeutics Inc Company Overview
4.4 APRUS Bio-Medical Innovations Pvt Ltd Company Overview
4.5 Arch Therapeutics Inc Company Overview
4.6 Baxter Healthcare Corp Company Overview
4.7 Baxter International Inc Company Overview
4.8 Beth Israel Deaconess Medical Center Inc Company Overview
4.9 Biomedica Management Corp Company Overview
4.10 Biom'Up SAS Company Overview
4.11 C. R. Bard Inc Company Overview
4.12 Cellphire Inc Company Overview
4.13 Ceramicos Para Aplicacoes Medicas SA Company Overview
4.14 Columbia University Company Overview
4.15 Covalent Medical, Inc. (Inactive) Company Overview
4.16 Covalon Technologies Ltd Company Overview
4.17 Cresilon Inc Company Overview
4.18 CryoLife Inc Company Overview
4.19 Endomedix Incorporated Company Overview
4.20 Entegrion Inc Company Overview
4.21 Ethicon US LLC Company Overview
4.22 ETX Pharma Inc Company Overview
4.23 Gamma Therapeutics Inc Company Overview
4.24 GATT Technologies BV Company Overview
4.25 gel-e Inc Company Overview
4.26 Haemostatix Ltd Company Overview
4.27 Hemostasis LLC Company Overview
4.28 HLL Lifecare Ltd Company Overview
4.29 Keratin Biosciences Inc Company Overview
4.30 Leader Biomedical Europe BV Company Overview
4.31 LifeBond Ltd Company Overview
4.32 Protege Biomedical Company Overview
4.33 Resorba GmbH Company Overview
4.34 Rice University Company Overview
4.35 Sanara MedTech Inc Company Overview
4.36 Sanofi Biosurgery Inc Company Overview
4.37 Sea Run Holdings Inc Company Overview
4.38 St Teresa Medical Inc Company Overview
4.39 Tectum Company Overview
4.40 The Medicines Company Company Overview
4.41 Therus Corporation Company Overview
4.42 Thrombotargets Corp Company Overview
4.43 United Health Products, Inc. Company Overview
4.44 University of Grenoble Alpes Company Overview
4.45 Virginia Commonwealth University Company Overview
4.46 Xcede Technologies Inc Company Overview
5 Topical Absorbable Hemostats- Recent Developments
5.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019
5.2 Nov 12, 2019: Cook Medical’s leadership updates in Asia-pacific reinforce focus on growth and physician relationships
5.3 Nov 05, 2019: Stryker signs agreement to acquire Wright Medical for $5.4bn
5.4 Oct 31, 2019: gel-e announces breakthrough status designation from the U.S. Food and Drug Administration (FDA) for its first internal-use flowable device
5.5 Oct 31, 2019: Sanofi Q3 well on track
5.6 Oct 30, 2019: The Medicines Company reports third-quarter 2019 financial results and achievement of major milestones for inclisiran
5.7 Oct 30, 2019: CryoLife reports third quarter 2019 financial results
5.8 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019
5.9 Oct 24, 2019: Baxter reports preliminary third quarter 2019 operating results
5.10 Oct 24, 2019: Anika reports third quarter 2019 financial results
6 Appendix
6.1 Methodology
6.2 About the Author
6.3 Contact Us
6.4 Disclaimer
List of Tables
Table 1: Topical Absorbable Hemostats - Pipeline Products by Stage of Development
Table 2: Topical Absorbable Hemostats - Pipeline Products by Segment
Table 3: Topical Absorbable Hemostats - Pipeline Products by Territory
Table 4: Topical Absorbable Hemostats - Pipeline Products by Regulatory Path
Table 5: Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date
Table 6: Topical Absorbable Hemostats - Ongoing Clinical Trials
Table 7: Topical Absorbable Hemostats Companies - Pipeline Products by Stage of Development
Table 8: Topical Absorbable Hemostats - Pipeline Products by Stage of Development
Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 10: PuraStat Hemostat - Product Status
Table 11: PuraStat Hemostat - Product Description
Table 12: TDM-511 - Product Status
Table 13: TDM-511 - Product Description
Table 14: TDM-623 - Product Status
Table 15: TDM-623 - Product Description
Table 16: 3-D Matrix Ltd - Ongoing Clinical Trials Overview
Table 17: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of Purastat Absorbable Haemostatic Material for the Management of Bleeding after Open Liver Resection
Table 18: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery
Table 19: PuraStat Hemostat - A Multicenter Prospective Observational Study to Evaluate the Utilization, Effectiveness and Safety of Purastat in the Management of Gastrointestinal Bleeding
Table 20: PuraStat Hemostat - The Hemostatic Potential of TDM-621 on Ascending Aortic Surgery
Table 21: Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 22: Hemaseel Thrombin Haemostatic Agent - Product Status
Table 23: Hemaseel Thrombin Haemostatic Agent - Product Description
Table 24: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Hemostatic Patch - Product Status
Table 26: Hemostatic Patch - Product Description
Table 27: APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Deep Wound Hemostat - Product Status
Table 29: Deep Wound Hemostat - Product Description
Table 30: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 31: AC5 - V - Product Status
Table 32: AC5 - V - Product Description
Table 33: AC5 Surgical Hemostatic Device - Product Status
Table 34: AC5 Surgical Hemostatic Device - Product Description
Table 35: AC5 Topical Gel - Product Status
Table 36: AC5 Topical Gel - Product Description
Table 37: Arch Therapeutics Inc - Ongoing Clinical Trials Overview
Table 38: AC5 Topical Gel - AC5 Topical Gel Skin Sensitization Study
Table 39: Baxter Healthcare Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Celstat Topical Hemostatic Dressing - Product Status
Table 41: Celstat Topical Hemostatic Dressing - Product Description
Table 42: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 43: FloSeal Matrix Hemostatic Sealant - Product Status
Table 44: FloSeal Matrix Hemostatic Sealant - Product Description
Table 45: Hemopatch - Product Status
Table 46: Hemopatch - Product Description
Table 47: Hemopatch - Dural Defects - Product Status
Table 48: Hemopatch - Dural Defects - Product Description
Table 49: TISSEEL - Product Status
Table 50: TISSEEL - Product Description
Table 51: Baxter International Inc - Ongoing Clinical Trials Overview
Table 52: FloSeal Matrix Hemostatic Sealant - Blood-saving Effect of Combined Intravenous Tranexamic Acid with Topical Floseal Application, a Comparison with Intravenous Tranexamic Acid Only in Total Hip Arthroplasty
Table 53: FloSeal Matrix Hemostatic Sealant - Effectiveness of Gelatin Matrix with Human Derived Thrombin on Blood Loss, Surgical Time, Hospital Stay and Complications in Adolescents Undergoing Spine Surgery for Adolescent Idiopathic Scoliosis: A Randomized Clinical Trial
Table 54: FloSeal Matrix Hemostatic Sealant - Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery
Table 55: FloSeal Matrix Hemostatic Sealant - Impact of Electrocoagulation Versus a Gelantine-Thrombin Matrix Sealant (FloSeal) on Ovarian Reserve After Laparoscopic Stripping of Ovarian Endometriomas
Table 56: FloSeal Matrix Hemostatic Sealant - Intraoperative Bleeding Control with Thrombin-Gelatin-Matrix (Floseal) in Advanced Gynecologic Surgery. A Case-control Study with Special Focus on Hemostasis in Patients with Primary or Secondary Coagulapathies
Table 57: FloSeal Matrix Hemostatic Sealant - Management of Persistent Anterior Epistaxis Using Floseal Hemostatic Matrix vs. Traditional Nasal Packing: A Prospective Randomized Controlled Trial
Table 58: FloSeal Matrix Hemostatic Sealant - Prospective, Randomised, Controlled Investigation Comparing the Safety and Performance of 032-11 Surgical Haemostat with FLOSEAL Haemostatic Matrix in Cardiac Surgery and Thoracic Aortic Surgery
Table 59: FloSeal Matrix Hemostatic Sealant - The Role of Floseal in the Prevention of Lymphocele and Lymphatic Ascites After Lymph Node Dissection for Gynecologic Cancer: a Randomized Controlled Trial
Table 60: TISSEEL - Modified Muller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue
List of Figures
Figure 1: Topical Absorbable Hemostats - Pipeline Products by Stage of Development
Figure 2: Topical Absorbable Hemostats - Pipeline Products by Segment
Figure 3: Topical Absorbable Hemostats - Pipeline Products by Territory
Figure 4: Topical Absorbable Hemostats - Pipeline Products by Regulatory Path
Figure 5: Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date
Figure 6: Topical Absorbable Hemostats - Ongoing Clinical Trials
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 3-D Matrix Ltd
  • Angiotech Pharmaceuticals Inc
  • Anika Therapeutics Inc
  • APRUS Bio-Medical Innovations Pvt Ltd
  • Arch Therapeutics Inc
  • Baxter Healthcare Corp
  • Baxter International Inc
  • Beth Israel Deaconess Medical Center Inc
  • Biomedica Management Corp
  • Biom'Up SAS
  • C. R. Bard Inc
  • Cellphire Inc
  • Ceramicos Para Aplicacoes Medicas SA
  • Columbia University
  • Covalent Medical, Inc. (Inactive)
  • Covalon Technologies Ltd
  • Cresilon Inc
  • CryoLife Inc
  • Endomedix Incorporated
  • Entegrion Inc
  • Ethicon US LLC
  • ETX Pharma Inc
  • Gamma Therapeutics Inc
  • GATT Technologies BV
  • gel-e Inc
  • Haemostatix Ltd
  • Hemostasis LLC
  • HLL Lifecare Ltd
  • Keratin Biosciences Inc
  • Leader Biomedical Europe BV
  • LifeBond Ltd
  • Protege Biomedical
  • Resorba GmbH
  • Rice University
  • Sanara MedTech Inc
  • Sanofi Biosurgery Inc
  • Sea Run Holdings Inc
  • St Teresa Medical Inc
  • Tectum
  • The Medicines Company
  • Therus Corporation
  • Thrombotargets Corp
  • United Health Products, Inc.
  • University of Grenoble Alpes
  • Virginia Commonwealth University
  • Xcede Technologies Inc
Note: Product cover images may vary from those shown